For any normal field of science, the conclusion that "there is more to (fill in a disease) than (fill in leading but unproved hypothesis) alone" wouldn't cause anyone to bat an eye. After all, science is supposed to consider all reasonable ideas. But Alzheimer's disease is not your normal field of science.
The J. David Gladstone Institutes and drug giant Merck & Co. have struck a deal that will launch a new effort by the institutes to see its discoveries turned into commercial therapies.
The J. David Gladstone Institutes and Merck & Co., Inc. today announced a major collaboration and license agreement for research and development of drugs to treat neurodegenerative diseases, including Alzheimer's disease, that are linked to apoE-regulated mechanisms in the body.
The J. David Gladstone Institutes is ranked North America's second best place to work in academia, according to The Scientist magazine's annual survey published in its October issue. The Gladstone Institutes, whose scientists investigate the causes of such illnesses as cardiovascular disease, HIV/AIDS, and Alzheimer's disease, placed second among the 40 institutions represented from North America.
Researchers at the Gladstone Institute of Neurological Disease (GIND) have identified a potential new avenue for reducing the build up of toxic amyloid ß (Aß) proteins, which are suspected of causing Alzheimer's disease (AD). They discovered that the enzyme cathepsin B (CatB) effectively destroys small as well as large clusters of Aß. Previously, CatB had been suspected of increasing Aß production in AD patients.
The J. David Gladstone Institutes honored Haile T. Debas, MD, and Lloyd H. Holly Smith, MD, for their instrumental roles developing the UCSF-affiliated research institutes.
Last year, the J. David Gladstone Institutes ranked 12th on the Scientist magazine's list of best places for post-doctoral fellows to work. It wasn't good enough.
The long race to develop a cure, or even a viable treatment, for Alzheimer's disease is quickly turning into a sprint as the Baby Boomer generation heads toward old age and the country faces what could be a health care disaster if the disease is allowed to run rampant.
A question long debated among Alzheimer's disease researchers has been definitively answered by scientists at the Gladstone Institute of Neurological Disease in San Francisco.
The J. David Gladstone Institutes is North America's best institutional work environment for life sciences postdoctoral fellows, according to The Scientist's annual Best Places to Work for Postdocs survey, published in the March 1 issue.
Researchers for the first time have created a three-dimensional image of apolipoprotein E, a protein long associated with cardiovascular disease and more recently with Alzheimer's disease, as it appears when it is bound to fat-like substances known as lipids.
